Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 15;11:392–404. doi: 10.1016/j.dadm.2019.03.004

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Published by Elsevier Inc. on behalf of the Alzheimer's Association.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 3 — Effects of AD Braak stage and ApoE genotype on IDE gene expression in human postmortem brains. Fresh frozen postmortem human frontal lobe tissue samples from cases with Braak stage [B] 0-2 (normal aging), B3-4 (moderate AD), or B5-6 (severe AD) were used to measure IDE mRNA expression by qRT-PCR analysis with results normalized to β-actin mRNA measured simultaneously in the same samples. Statistical comparisons assessed changes in IDE mRNA expression in relation to: (A) AD severity in cases with ApoE ε3/ε3 genotype, (B) ApoE genotype in cases with moderate AD (B3-4), and (C) ApoE genotype in cases with severe AD. Graphs depict box plots with mean levels of expression (horizontal bars), 95% confidence interval limits (upper and lower boundaries of the boxes), and ranges (upper and lower stems). One-way ANOVA with post hoc repeated measures Tukey tests were used for intergroup comparisons. Abbreviations: AD, Alzheimer's disease; ANOVA, analysis of variance; ApoE, apolipoprotein E; IDE, insulin-degrading enzyme; qRT-PCR, quantitative reverse transcriptase polymerase chain reaction.